Abstract:Background: Hypoxia is a hallmark of the physical microenvironment of solid tumors. As a key factor that regulates tumor development and progression, hypoxia can reprogram the expression of multiple genes, whose biological function and molecular mechanism in cancer remain largely unclear. The mitochondrial ribosome protein family consists of nuclear-encoded mitochondrial proteins that are responsible for protein synthesis in the mitochondria. Methods: A high-throughput RNA sequencing assay was carried out to identify differentially expressed mRNAs between breast cancer tissues and adjacent normal tissues as well as breast tumors with metastasis and those without metastasis. Our clinical samples and TCGA database were analyzed to observe the clinical value of mitochondrial ribosome protein L52 (MRPL52) in human breast cancer. Potent hypoxia response elements in the promoter region of MRPL52 were identified and validated by chromatin immunoprecipitation and luciferase reporter assays. Functional experiments were performed using breast cancer cell lines with MRPL52 ectopic expression and knockdown cultured in a 20% or 1% O2 environment. Results: MRPL52 expression was upregulated in human breast cancer and was significantly associated with aggressive clinicopathological characteristics and a higher metastatic risk of breast cancer patients. We found that the overexpression of MRPL52 in breast cancer is induced by hypoxia-inducible factor-1 in response to hypoxic exposure. The role of MRPL52 in suppressing apoptosis and promoting migration and invasion of hypoxic breast cancer cells was demonstrated by our experimental evidence. Mechanistically, MRPL52 promoted PTEN-induced putative kinase 1 /Parkin-dependent mitophagy to remove oxidatively damaged mitochondria and prevent uncontrolled reactive oxygen species (ROS) generation, thus repressing activation of the mitochondrial apoptotic cascade. Additionally, MRPL52 augmented epithelial-mesenchymal transition, migration and invasion of hypoxic breast cancer cells by activating the ROS-Notch1-Snail signaling pathway. Benefited from this bidirectional regulatory mechanism, MRPL52 is responsible for maintaining ROS levels in a window that can induce tumorigenic signal transduction without causing cytotoxicity in hypoxic breast cancer cells. Conclusions: This work elucidates the molecular mechanism by which MRPL52 mediates hypoxia-induced apoptotic resistance and metastatic initiation of breast cancer, and provides new insights into the interplay between cancer and the tumor microenvironment.

A Mitochondrial EglN1-AMPKa Axis Drives Breast Cancer Progression by Enhancing Metabolic Adaptation to Hypoxic Stress

EglN2 associates with the NRF1-PGC1α complex and controls mitochondrial function in breast cancer.

EglN2 associates with the <scp>NRF</scp>1‐<scp>PGC</scp>1α complex and controls mitochondrial function in breast cancer

Interplay Of Mkp-1 And Nrf2 Drives Tumor Growth And Drug Resistance In Non-Small Cell Lung Cancer

AMP‐activated Protein Kinase Regulates Cancer Cell Growth and Metabolism Via Nuclear and Mitochondria Events

EglN2 positively regulates mitochondrial function in breast cancer.

HIF-1-induced mitochondrial ribosome protein L52: a mechanism for breast cancer cellular adaptation and metastatic initiation in response to hypoxia

Hypoxia Promotes Breast Cancer Cell Growth by Activating a Glycogen Metabolic Program

Energy Stress-activated AMPK Phosphorylates Snail1 and Suppresses Its Stability and Oncogenic Function

Hypoxia-induced NAD+ Interventions Promote Tumor Survival and Metastasis by Regulating Mitochondrial Dynamics.

Mitochondrial Respiration Defects in Cancer Cells Cause Activation of Akt Survival Pathway Through A Redox-Mediated Mechanism

The Critical Role of AMPK in Driving Akt Activation under Stress, Tumorigenesis and Drug Resistance

Cancer EV stimulate endothelial glycolysis to fuel protein synthesis via mTOR and AMPKα activation

Tumor hypoxia promotes MAPK signaling by inhibiting prolyl hydroxylation of SOS1

Regulation of AMPK-related Glycolipid Metabolism Imbalances Redox Homeostasis and Inhibits Anchorage Independent Growth in Human Breast Cancer Cells

Epithelial–Mesenchymal Transition Suppresses AMPK and Sensitizes Cancer Cells to Pyroptosis under Energy Stress

Oxidized ATM-mediated glycolysis enhancement in breast cancer-associated fibroblasts contributes to tumor invasion through lactate as metabolic coupling

NEAT1 is Essential for Metabolic Changes That Promote Breast Cancer Growth and Metastasis

Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells

Mitochondrial creatine kinase 1 in non-small cell lung cancer progression and hypoxia adaptation

AMPK maintains TCA cycle through sequential phosphorylation of PDHA to promote tumor metastasis